Iodine deficiency is a major cause of impaired mental development, goitre, and cretinism in many parts of the world. Because existing immunization programmes can be used to deliver oral iodized oil (OIO) to infants at risk, it was important to know whether OIO could adversely affect the antibody response to vaccines, such as trivalent oral poliovirus vaccine (OPV).
Introduction
Although the use of iodized salt is regarded as the long-term solution to iodine deficiency disorders (IDD) (1), interim measures for iodine supplements are needed in areas where iodized salt is not yet available or widely used (2) . One suggestion for areas with a high risk of IDD and child mortality is to provide oral iodized oil (OIO) supplements to infants through the existing immunization services (3) . The extensive coverage provided by these services would reduce the overhead costs of OIO supplementation (4) . However, the administration of OIO at the same time as trivalent oral poliovirus vaccine (OPV) has not been recommended because of the absence of clinical studies on the effect of iodized oil on the immune response of vaccinees to OPV (5) .
The effect of iodized oil on the infectivity of poliovirus vaccine has been studied in vitro (6) ; the oil contained 480 mg iodine per ml and, when mixed with an equal volume of vaccine, was found to reduce poliovirus infectivity in the rapid stability test (RST). This test consisted in incubating monovalent Sabin strains (poliovirus types 1, 2, or 3) or trivalent OPV (from different sources of manufacture) with poppyseed oil (alone and with addition of iodine), followed by determining virus infectivity in cell culture. Reduction in titres ranged from about 1 to 5 log units, depending markedly on the time of incubation, the vaccine source, and poliovirus type (type 3 being the most susceptible to iodine treatment). However, when iodized oil and poliovirus were mixed and assayed immediately, no reduction in infectivity was observed. The authors of the study concluded that, although oral administration of iodized oil at the same time as OPV was unlikely to impair seroconversion in the recipient, clinical confirmation was required before the procedure could be recommended by the WHO Expanded Programme on Immunization (EPI) (6) .
Oral iodized oil supplementation has recently been shown to improve infant survival in a clinical trial in Indonesia in which infants received OIO or placebo immediately after their first dose of OPV (7) . While this trial suggested that OIO improved infant survival, it was still not known whether OIO interfered with OPV. The aim of the present study was to examine the effect of OIO on the antibody response to OPV in the same clinical trial.
Materials and methods
The study design Ð a randomized, double-masked, placebo-controlled clinical trial Ð has been described in detail elsewhere (7) . The study population was drawn from an area of mild-to-severe IDD in Subang, West Java, Indonesia. The study was approved by the Institutional Review Board of the Johns Hopkins School of Medicine and by the ethical committees of WHO, Hasan Sadikin Hospital, University Pajajaran, and the Indonesian Ministry of Health. Written informed consent was obtained from a parent or guardian for all participants in the study. Iodine supplementation was given to infants aged 8 weeks during their first EPI contact, at which time they also received oral poliovirus and diphtheria± pertussis±tetanus vaccines. Placebo (poppy-seed oil) or OIO (100 mg Lipiodol, Laboratoire Guerbet, Aulnay-sous-Bois, France) was administered by mouth immediately after the first dose of OPV. The infants completed the EPI immunization schedule with two additional visits at four-week intervals and a final follow-up evaluation at 6 months of age.
Serum samples were collected from each infant at enrolment (8 weeks) and at follow-up (6 months) and kept frozen at ±80 o C. Upon thawing, the sera were heat-inactivated at 56 o C for 30 min, diluted 1:4 in assay medium, and refrozen in aliquots until assayed for antibody activity in poliovirus microneutralization tests, as previously described (8, 9) , using duplicate serial twofold serum dilutions and attenuated poliovirus strains TA-4, TB-3a, and TC-3a (poliovirus types 1, 2, and 3, respectively). The International Reference Serum 96/202 (National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, England (10)), containing 25, 50 and 5 IU of antibody activity against poliovirus types 1, 2, and 3, respectively, was used to calibrate inhouse reference sera against each poliovirus serotype according to directions provided by the supplier. The baseline (pre-immune) and follow-up (postimmune) sera from each subject in the study were assayed at the same time. Virus neutralization was scored by microscopic examination of replicate cultures at each dilution of serum after 10 days of incubation. The 50% endpoint dilutions were calculated (11) and the results expressed both as reciprocal log 2 dilutions and in IU. The lowest detectable level of neutralizing antibody activity was 2 log 2 units; sera with no detectable neutralizing antibody activity were therefore assigned a log 2 dilution value of 1.5. Sera with high levels of neutralizing antibody activity, exceeding the dilution range of the test, were assigned a log 2 dilution value of 12.5. The log-fold increase (LFI) in neutralizing-antibody activity was calculated for each subject with and without an adjustment for estimated decline in maternally derived antibody over the study period. The mean time from enrolment to follow-up was 120 days (95% confidence interval (CI): + 0.72 days), and an adjustment of four antibody half-lives was applied uniformly to the pre-immune titres for all samples.
All poliovirus neutralizing antibody assays were conducted under masked conditions. After preliminary analysis of the neutralizing antibody results to confirm the applicability of the statistical approaches to be used, the identity, treatment allocation, and other characteristics of the subjects were disclosed. Maximum likelihood fitting in contingency table tests and analysis of variance were used to determine whether the treatment allocation groups differed according to sex, age at enrolment, or other factors that might confound the analysis of the main treatment effect. Geometric mean titres of preimmune and postimmune sera and the mean LFI were calculated for the iodine and placebo groups. Analysis of variance was used to evaluate the effect of supplementation with iodized oil on the neutralizing antibody responses for each of the three poliovirus serotypes (12) .
Results
Of the 617 infants enrolled in the study, 307 (49.8%) received OIO and 310 (50.2%) the placebo; 88 infants dropped out of the study before the age of 6 months and 22 died prior to follow-up. Thus, only 507 infants were reviewed at 6 months of age, but serum samples were not available for 29 of them, leaving a total of 478 (238 and 240 in the placebo and iodine groups, respectively) pairs of pre-immune and postimmune sera for evaluation. Maternal and infant characteristics in both groups are presented in Table 1 as frequencies (and percentages), or means (+ 95% CI). The treatment groups did not differ significantly with regard to any of the characteristics examined.
Geometric mean titres and confidence intervals for the placebo and iodine treatment groups are given in Table 2 . Mean titres were higher after vaccination, but in many cases the individual postvaccination titres were lower than the corresponding pre-vaccination titres. There were 42, 9, and 43 such instances for poliovirus types 1, 2, and 3, respectively; these occurred with similar frequencies in the placebo and iodine treatment groups (data not shown). High levels of neutralizing antibodies in the pre-vaccination sera make it difficult to interpret the seroconversion rates or LFI following immunization with OPV. Therefore adjustment was made for the presumed decline of maternal antibodies during the 4 months between the baseline and follow-up blood collecCompatibility of oral iodine and oral poliovirus vaccine tions, assuming a half-life of 1 month for the neutralizing antibody activity (13) . The LFI values are shown in Table 2 . Analysis of variance indicated that the differences in mean titre or LFI between the placebo and iodine groups were not significant for any of the poliovirus serotypes. The range of measured neutralizing antibody activity was 0.01±14 IU for type 1, 0.05±49 IU for type 2, and 0.01±11 IU for type 3 poliovirus. After immunization, 2 (0.4%), 1 (0.2%), and 16 (3.3%), respectively, of the infants had no detectable neutralizing antibodies to poliovirus types 1, 2, and 3. After adjusting for loss of maternal antibody, 16 (3.3%), 2 (0.4%), and 12 (2.5%) of the infants showed no increase in titre over pre-vaccination levels. The incidence of these non-responders did not differ between the placebo and iodine treatment groups (P = 0.299, 0.094, and 0.988 for poliovirus types 1, 2, and 3, respectively). For poliovirus type 1, rates for seroconversion, defined as an adjusted LFI of 52, were 97.5% and 95.8% in the placebo and iodine treatment groups, respectively. The corresponding rates for the placebo and iodine treatment groups were, respectively, 100% and 99.2% for poliovirus type 2, and 97.5% in both groups for poliovirus type 3. After immunization, the numbers of samples testing above the upper limit of the measurement range were 188 (39.3%), 140 (29.3%), and 70 (14.6%) for poliovirus types 1, 2, and 3, respectively, with similar frequencies in the placebo and iodine treatment groups. When analysis was restricted to those subjects who had post-vaccination titres within the measurable range of the assay, the placebo and iodine treatment groups did not differ in terms of mean titre or LFI for any of the poliovirus types.
Anthropometric and morbidity data were also evaluated. No anthropometric factor exerted a significant effect on neutralizing antibody titres to all three poliovirus serotypes, except for a highly significant effect of the infant's age at enrolment on pre-vaccination titres. As age increased from 6 to 10 weeks, the neutralizing activity to all three poliovirus types in pre-vaccination sera declined, as would be expected for antibody of maternal origin. The effect of fluid supplements (in addition to breastfeeding) on the antibody response to type-3 vaccine was significant (P = 0.023). Age at enrolment affected responses to type-1 and type-2 vaccines (P = 0.035 and 0.0013, respectively). Infants with diarrhoeal illness concurrent with the first, second, or third vaccination dose had lower mean increases in neutralizing antibody activity to all three poliovirus types, but the difference was significant only for type-1 poliovirus (P = 0.020). There was no effect on increase in titre due to the presence of cough concurrent with vaccination. However, smaller increases in titres against type-1 poliovirus were associated with fever (P = 0.042) or difficult breathing (P = 0.044) at the time of the first visit.
Discussion
In this study the levels of neutralizing antibodies to all three poliovirus serotypes were similar to those reported recently by other investigators for infants vaccinated with OPV (14, 15) . We found no evidence that oral iodine supplementation reduced the immune response to OPV. A difference of <0.6 log 2 units in mean titre between the groups that received placebo or iodine would have been significant for any of the serotypes.
A number of host and environmental factors, such as breastfeeding, nutritional status and concurrent enteric infections, may influence the response to OPV (16) . Infection with nonpolio a The number of subjects (n ) is shown for each group (placebo and iodine treatment). Group mean log 2 titres are the reciprocal 50% endpoint dilutions calculated from duplicate serial twofold dilutions in poliovirus microneutralization assays. Mean titres are shown with their 95% confidence intervals and are also expressed in International Units (IU). The log-fold increase (LFI) in titre is the difference between post-vaccination titre and pre-vaccination titre. The adjusted LFI is the difference between post-vaccination titre and pre-vaccination titre adjusted for decline in maternal antibody over the follow-up period. b iod-plac, iodine-placebo groups.
enteroviruses, season of vaccination, and level of maternal education had significant effects on the responses to OPV in one study (17) , but it appears that nutrition had no such effect (18±20). Age, sex, and the presence of other enteroviruses in stools did not have a significant effect (20) . Concurrent diarrhoeal illness impaired early seroconversion with type-2 and type-3 poliovirus (21). We examined several of these factors to determine whether they were significant or might bias our comparison between the placebo and iodine groups. Both groups were very similar with regard to distribution of these factors (Table 1) , which did not exhibit a significant effect on the antibody responses to the three serotypes taken together (Table 3) . We did observe significant effects on the response to individual serotypes associated with the following factors: fluid supplements to breastfeeding (type-3 vaccine, P = 0.023), diarrhoeal illness concurrent with immunization (type-1 vaccine, P = 0.020), and age at enrolment and first dose of OPV (type-1 and type-2 vaccines, P = 0.035 and 0.0013, respectively). However, it is important to note that our study was not specifically designed to evaluate the effects of these factors, and further investigations would have to determine whether their influences on neutralizingantibody activity are real. A high proportion of infants had measurable levels of poliovirus-neutralizing antibodies prior to immunization. Other workers have made similar observations (14, 15) . Pre-vaccination titres to all three poliovirus serotypes were negatively correlated with age at enrolment. The effect was highly significant for all three poliovirus types, consistent with the interpretation that this neutralizing-antibody activity was derived from the mother and declined with increasing age of the infant. A half-life of 1 month has been suggested for maternal antibodies to poliovirus (13) and we used this value to adjust prevaccination titres in the calculation of the log-fold increases in titre. To exclude any bias that might have arisen from making this adjustment, we also analysed the unadjusted log-fold increases in titre and the postvaccination titres themselves (results not shown).
The finding was the same as that obtained with the adjustmentÐi.e. administration of OIO had no effect on neutralizing-antibody responses to OPV. Iodine deficiency is a major cause of preventable mental deficiency and has increased overall infant mortality in many populations (22) . While iodized salt is regarded as the preferred long-term solution to IDD (1), interim measures are still needed (2) . Both replacement of iodine in irrigation water (23) and supplementation by administration of OIO (7) have been shown to decrease infant mortality, but the choice between alternative interim methods of iodine delivery depends on a careful review of local circumstances (24) . Iodization with water is often less satisfactory than use of iodized oil (25) . In at least some areas, the time of primary vaccination according to the EPI schedule could be the first opportunity to provide iodine supplements to the infant, and possibly to the mother. Our results show that OIO did not reduce the immune responses of infants to OPV, but did improve infant survival in the same cohort (7), suggesting that the timetables for immunization and OIO administration are compatible. We conclude that supplementation with OIO may be safely combined with delivery of the first dose of OPV in the EPI schedule. n Re Â sume Â La supple Â mentation en iode par voie buccale ne re Â duit pas la re Â ponse en anticorps neutralisants au vaccin antipoliomye Â litique buccal La suppleÂ mentation en huile iodeÂ e administre Â e par voie buccale constitue un moyen provisoire de re Â duire la preÂ valence des troubles dus a Á une carence en iode, a Á savoir notamment l'arrieÂ ration mentale, le goitre ou le creÂ tinisme. Les programmes de vaccination infantile pourraient se charger d'assurer cette suppleÂ mentation en iode aux enfants exposeÂ s au risque, si du moins cette intervention n'interfeÁ re pas avec la reÂ ponse immunitaire au vaccin antipoliomye Â litique buccal trivalent. C'est pour s'en assurer qu'un essai clinique randomise Â en double aveugle avec groupe placebo a e Â te Â effectueÂ a Á Subang, dans le Java occidental (IndoneÂ sie). A cette occasion, 617 nourrissons a Ã ge Â s de huit semaines ont rec Ëu soit de l'huile iode Â e (100 mg) soit un placebo constitue Â d'huile d'oeillette, par voie buccale, imme Â diatement apreÁ s administration de leur premieÁ re dose de vaccin antipoliomyeÂ litique buccal par le Programme eÂ largi de vaccination (PEV). La deuxie Á me et la troisieÁ me dose de vaccin ont e Â te Â ensuite administreÂ es a Á intervalles de 4 semaines et les enfants ont e Â te Â suivis jusqu'a Á l'a Ã ge de 6 mois.
On a deÂ termine Â le titre des anticorps dirigeÂ s contre le virus poliomyeÂ litique de type 1, 2 et 3 dans des pre Â -leÁ vements de seÂ rum effectueÂ s au moment de l'entreÂ e dans l'essai (a Á l'a Ã ge de 8 semaines) et pendant la peÂ riode de suivi (a Á l'a Ã ge de 6 mois) sur 478 enfants (238 et 240 paires de se Â rums provenant respectivement du groupe traiteÂ et du groupe placebo). Pour deÂ terminer le titre des anticorps seÂ riques, nous avons proceÂ de Â a Á des e Â preuves de microneutralisation du virus dans des conditions d'anonymat geÂ ne Â ral. Les re Â sultats eÂ taient exprime Â s sous la forme de l'inverse du log 2 de la dilution ainsi qu'en UI. Pour chaque sujet, nous avons calculeÂ l'accroissement logarithmique de l'activiteÂ des anticorps neutralisants avec ou sans correction pour tenir compte de la baisse du titre des anticorps d'origine maternelle pendant la dureÂ e de l'e Â tude. Pour deÂ terminer si le groupe traiteÂ et le groupe placebo diffeÂ raient eu eÂ gard au sexe, a Á l'a Ã ge, au recrutement ou a Á d'autres facteurs susceptibles de fausser l'analyse de l'effet du traitement, nous avons utiliseÂ la me Â thode du maximum de vraisemblance avec tables de contingence et proce Â de Â e Â galement par analyse de la variance. Nous avons calculeÂ les titres moyens geÂ omeÂ triques des seÂ rums avant et apre Á s vaccination ainsi que l'accroissement logarithmique moyen dans le groupe traiteÂ et le groupe placebo. Nous avons e Â galement appliqueÂ l'analyse de la variance pour e Â valuer l'effet de la suppleÂ mentation en iode au moyen d'huile iodeÂ e sur la re Â ponse en anticorps neutralisants vis-a Á -vis de chacun des trois seÂ rotypes de virus poliomyeÂ litique.
Les valeurs obtenues pour le titre des anticorps neutralisants dirigeÂ s contres les trois se Â rotypes viraux e Â taient analogues a Á celles que d'autres chercheurs ont trouveÂ es chez des nourrissons vaccineÂ s contre la poliomyeÂ lite par voie buccale. Nous n'avons rien releveÂ qui puisse inciter a Á penser que la supple Â mentation par de l'huile iodeÂ e diminue la re Â ponse immunitaire au vaccin buccal. Une diffeÂ rence entre les deux groupes de < 0,6 log 2 dans le titre moyen aurait eÂ te Â significative pour chacun des trois se Â rotypes. Le fait d'avoir pu constater que la suppleÂ mentation par de l'huile iode Â e ne reÂ duisait pas la reÂ ponse en anticorps a Á l'un ou l'autre des trois seÂ rotypes vaccinaux, nous permet de dire qu'il est possible de donner sans risque de l'huile iodeÂ e avec la premieÁ re dose de vaccin antipoliomyeÂ litique buccal selon le calendrier actuel du PEV.
Compatibility of oral iodine and oral poliovirus vaccine
Resumen Los suplementos orales de yodo no reducen la respuesta de produccio Â n de anticuerpos neutralizantes contra la vacuna antipoliomielõ Âtica oral La administracio Â n de suplementos de aceite yodado oral (AYO) es un meÂ todo provisional eficaz para reducir la prevalencia de los trastornos por carencia de yodo (TCY), que son causa de deterioro del desarrollo mental, bocio y cretinismo. Los programas de inmunizacio Â n infantil podrõ Âan encargarse de administrar el AYO a los lactantes en riesgo, a condicio Â n de que ello no interfiera en la respuesta de produccio Â n de anticuerpos contra la vacuna antipoliomielõ Âtica oral (OPV) trivalente. En consecuencia, se llevo Â a cabo un ensayo clõ Ânico aleatorizado en doble ciego en Subang, en el oeste de Java (Indonesia), en el que 617 lactantes de ocho semanas recibieron ya fuera AYO (100 mg) o bien un placebo (aceite de semilla de adormidera) por võ Âa oral inmediatamente despueÂ s de la primera dosis de OPV administrada por el Programa Ampliado de Inmunizacio Â n (PAI). Posteriormente se administraron la segunda y la tercera dosis de OPV a intervalos de cuatro semanas, y se hizo un seguimiento de los lactantes a la edad de 6 meses.
Se determinaron los tõ Âtulos de anticuerpos neutralizantes contra los serotipos 1, 2 y 3 del poliovirus en los sueros obtenidos en el momento del reclutamiento (a las 8 semanas de edad) y con ocasio Â n del examen de seguimiento (a los 6 meses) de 478 lactantes (238 y 240 pares de sueros de los grupos tratados con placebo y con yodo, respectivamente). Se analizo Â la actividad de anticuerpos de los sueros mediante pruebas de microneutralizacio Â n de poliovirus realizadas en condiciones de enmascaramiento. Los resultados se expresaron como el logaritmo binario de la inversa de las diluciones y en forma de UI. Se calculo Â el incremento logarõ Âtmico (IL) de la actividad de anticuerpos neutralizantes para cada sujeto con y sin ajuste en funcio Â n de la disminucio Â n estimada de los anticuerpos de origen materno durante el periodo de estudio. Se utilizo Â el ajuste de ma Â xima verosimilitud en las pruebas de tablas de contingencia y los ana Â lisis de la varianza para determinar si los grupos tratados con yodo y con placebo diferõ Âan segu Â n el sexo, la edad de reclutamiento u otros factores que hubiesen podido confundir el ana Â lisis del efecto terape Â utico principal. Se calcularon la media geomeÂ trica de los tõ Âtulos se Â ricos antes y despueÂ s de la inmunizacio Â n y el IL medio del grupo tratado y el grupo placebo. Se realizo Â un ana Â lisis de varianza para evaluar el efecto de los suplementos de aceite yodado en la respuesta de produccio Â n de anticuerpos neutralizantes para cada uno de los tres serotipos del poliovirus.
Los niveles de anticuerpos neutralizantes contra los tres serotipos virales fueron similares a los notificados recientemente por otros investigadores para los lactantes inmunizados con la OPV. No hallamos ninguna prueba de que la administracio Â n de suplementos orales de yodo redujera la respuesta inmunitaria a la OPV. Una diferencia < 0,6 log 2 unidades entre los tõ Âtulos medios del grupo placebo y el tratado con yodo habrõ Âa sido significativa para cualquiera de los serotipos. La observacio Â n de que el AYO no reducõ Âa la respuesta de produccio Â n de anticuerpos frente a ninguno de los tres serotipos de OPV indica que es posible administrar ese aceite sin ningu Â n riesgo al mismo tiempo que la primera dosis de OPV prevista en las pautas actuales del PAI.
